文献速递认知障碍与痴呆

脑源性神经营养因子Val66Met对显性遗传阿尔茨海默病疾病标志物的影响

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.
PubMed 文献 · Ann Neurol · 2018-08-25

在显性遗传阿尔茨海默病(DIAD)中,211名认知正常受试者(101名突变非携带者、110名突变携带者)接受为期3.5年的认知、神经影像和脑脊液评估。突变携带者中,Met66携带者较Val66纯合子记忆下降快4倍、海马体积损失快16倍、脑脊液tau和ptau181升高快6倍;BDNF对皮质β-淀粉样蛋白积累或脑脊液Aβ42变化无影响。非携带者中BDNF基因型对各项指标变化均无影响。

要点

  • DIAD突变携带者中,Met66携带者较Val66纯合子记忆下降快4倍、海马体积损失快16倍、脑脊液tau和ptau181升高快6倍。
  • BDNF基因型不影响突变携带者皮质β-淀粉样蛋白积累速率或脑脊液Aβ42水平变化。
  • 非携带者中BDNF基因型对认知、脑体积、皮质β-淀粉样蛋白积累及脑脊液tau、ptau181、Aβ42变化均无影响。

核心结论

  • 与散发性AD一样,在DIAD突变携带者中,β-淀粉样蛋白对认知功能、脑体积损失和脑脊液tau的不利影响在Val66纯合子中较小。
  • BDNF Val66Met多态性应被视为当前DIAD和散发性AD治疗与预防试验中临床试验结局的潜在调节因素。

研究设计与样本

  • 研究纳入211名受试者(101名突变非携带者、110名突变携带者),均为临床痴呆评定量表全局评分为0的认知正常者,作为显性遗传阿尔茨海默病网络的一部分,在3.5年内完成认知功能、神经影像和脑脊液采样评估。

主要发现

  • 突变携带者中,Met66携带者较Val66纯合子记忆下降快4倍、海马体积损失快16倍、脑脊液tau和ptau181升高快6倍。
  • 突变携带者中,BDNF不影响皮质β-淀粉样蛋白积累速率或脑脊液Aβ42水平变化。
  • 突变非携带者中,BDNF基因型对认知变化、脑体积、皮质β-淀粉样蛋白积累或脑脊液tau、ptau181和Aβ42任何测量指标的变化均无影响。

临床怎么用

  • 作者认为,BDNF Val66Met多态性应被视为当前DIAD和散发性AD治疗与预防试验中临床试验结局的潜在调节因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous studies suggest that the brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism may influence symptom onset in Alzheimer's disease (AD). Our recent cross-sectional findings suggest that Met66 may influence clinical expression in dominantly inherited AD (DIAD) through its effects on tau. However, it remains unclear whether carriage of Met66 in DIAD results in faster increases in cerebrospinal fluid (CSF) tau and ptau181 , and whether these increases are associated with accelerated brain volume loss and memory decline. METHODS: A total of 211 subjects (101 mutation noncarriers, 110 mutation carriers), who were cognitively normal, as defined by a Clinical Dementia Rating global score of 0, completed assessments of cognitive function, neuroimaging, and CSF sampling over 3.5 years as part of the Dominantly Inherited Alzheimer's Network. RESULTS: In mutation carriers, Met66 carriers showed faster memory decline (4×), hippocampal volume loss (16×), and CSF tau and ptau181 increases (6×) than Val66 homozygotes. BDNF did not influence rates of cortical β-amyloid accumulation or change in CSF Aβ42 levels in mutation carriers. In mutation noncarriers, BDNF genotype had no effect on change in cognition, brain volume, cortical β-amyloid accumulation, or change in any CSF measures of tau, ptau181 , and CSF Aβ42 . INTERPRETATION: As in sporadic AD, the deleterious effects of β-amyloid on cognitive function, brain volume loss, and CSF tau in DIAD mutation carriers are less in Val66 homozygotes. The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD. Ann Neurol 2018;84:424-435.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Lim YY, Hassenstab J, Goate A, et al. Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Ann Neurol. 2018. PMID: 30014553. doi:10.1002/ana.25299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。